Some of the experimental uses for the Lentivirus vector have been in gene therapy of diseases like Diabetes mellitus, Murine haemophilia A, prostate cancer, chronic granulomatous disease, and vascular gene therapy.
12.
About 5-10 % of people with haemophilia A are affected because they make a dysfunctional version of the factor VIII protein, while the remainder are affected because they produced factor VIII in insufficient amounts ( quantitative deficiency ).
13.
Other diseases mentioned are high altitude pulmonary edema, Vogt-Koyanagi-Harada syndrome ( DRB1 * 0405, see above table for Japanese ), HIV resistance in the US, and haemophilia A ( anti-FVIII inhibitor response ).
14.
The vector targets the haematopoietic cells in order to increase the amount of factor VIII, which is affected in haemophilia A . But this continues to be a subject of study as the lentivirus vector was not completely successful in achieving this goal.
15.
"' Turoctocog alfa "'( trade name "'NovoEight "') is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A . It is marketed by Novo Nordisk.
16.
Haemophilia A, is a recessive X-linked genetic disorder resulting in a deficiency of functional clotting Factor VIII . Haemophilia C, is an autosomal genetic disorder involving a lack of functional clotting Factor XI . Haemophilia C is not completely recessive, as heterozygous individuals also show increased bleeding.
